spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Prasugrel 

 HSMN NewsFeed - 29 Jan 2020
CytoSorb(R) is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Devices Regulatory Product Launch
 HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Aug 2013
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
Diagnostics Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 1 Nov 2011
Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution
 HSMN NewsFeed - 9 Mar 2011
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
Diagnostics Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 16 Nov 2010
Mortality Data Presented for Patients Treated with Effient(R) Who Underwent Isolated Coronary Artery Bypass Surgery
Biopharmaceuticals Cardiology Surgery
 HSMN NewsFeed - 16 Nov 2010
GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI
Diagnostics Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 15 Mar 2010
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCI
Biopharmaceuticals Diagnostics Cardiology
 HSMN NewsFeed - 5 Jan 2010
New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 19 Nov 2009
AstraZeneca Submits US New Drug Application for Ticagrelor (BRILINTA(TM)), an Investigational Antiplatelet Agent
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Nov 2009
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Sep 2009
Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Jun 2009
Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2009
Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 21 May 2009
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Apr 2009
World-First Launch of New Heart Drug
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 23 Feb 2009
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Feb 2009
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 31 Dec 2008
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Dec 2008
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2008
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Mar 2008
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 4 Nov 2007
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 16 Jan 2007
Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients With Acute Coronary Syndrome
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Oct 2006
New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
Prasugrel
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.